Your browser doesn't support javascript.
loading
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin.
Woodhouse, Ryan; Li, Meijuan; Hughes, Jason; Delfosse, David; Skoletsky, Joel; Ma, Pei; Meng, Wei; Dewal, Ninad; Milbury, Coren; Clark, Travis; Donahue, Amy; Stover, Dan; Kennedy, Mark; Dacpano-Komansky, Jennifer; Burns, Christine; Vietz, Christine; Alexander, Brian; Hegde, Priti; Dennis, Lucas.
Afiliación
  • Woodhouse R; Regulatory Affairs, Foundation Medicine, Inc, Cambridge, Massachusetts, United States of America.
  • Li M; Biometrics and Biomarkers, Foundation Medicine, Inc, Cambridge, Massachusetts, United States of America.
  • Hughes J; Computational Biology, Foundation Medicine, Inc, Cambridge, Massachusetts, United States of America.
  • Delfosse D; Development Operations, Foundation Medicine, Inc, Cambridge, Massachusetts, United States of America.
  • Skoletsky J; Development Operations, Foundation Medicine, Inc, Cambridge, Massachusetts, United States of America.
  • Ma P; Biometrics and Biomarkers, Foundation Medicine, Inc, Cambridge, Massachusetts, United States of America.
  • Meng W; Biometrics and Biomarkers, Foundation Medicine, Inc, Cambridge, Massachusetts, United States of America.
  • Dewal N; Biometrics and Biomarkers, Foundation Medicine, Inc, Cambridge, Massachusetts, United States of America.
  • Milbury C; Development Operations, Foundation Medicine, Inc, Cambridge, Massachusetts, United States of America.
  • Clark T; Formerly Assay Development, Foundation Medicine, Inc, Cambridge, Massachusetts, United States of America.
  • Donahue A; Assay Development, Foundation Medicine, Inc, Cambridge, Massachusetts, United States of America.
  • Stover D; Laboratory Operations, Foundation Medicine, Inc, Cambridge, Massachusetts, United States of America.
  • Kennedy M; Computational Biology, Foundation Medicine, Inc, Cambridge, Massachusetts, United States of America.
  • Dacpano-Komansky J; Medical Device Global Regulatory Affairs, Novartis Corporation, Cambridge, Massachusetts, United States of America.
  • Burns C; Development Operations, Foundation Medicine, Inc, Cambridge, Massachusetts, United States of America.
  • Vietz C; Product Development, Foundation Medicine, Inc, Cambridge, Massachusetts, United States of America.
  • Alexander B; Clinical Development, Foundation Medicine, Inc, Cambridge, Massachusetts, United States of America.
  • Hegde P; Assay Development, Foundation Medicine, Inc, Cambridge, Massachusetts, United States of America.
  • Dennis L; Franchise Development, Foundation Medicine, Inc, Cambridge, Massachusetts, United States of America.
PLoS One ; 15(9): e0237802, 2020.
Article en En | MEDLINE | ID: mdl-32976510
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Bioensayo / Genómica / Ácidos Nucleicos Libres de Células / Neoplasias Límite: Humans Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Bioensayo / Genómica / Ácidos Nucleicos Libres de Células / Neoplasias Límite: Humans Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos